Future oncology (London, England) · 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Протокол клинического исследованияСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nooka Ajay K, Weisel Katja, van de Donk Niels Wcj, Routledge David, Otero Paula Rodriguez, Song Kevin, Quach Hang, Callander Natalie, Minnema Monique C, Trudel Suzanne, Jackson Nicola A, Ahlers Christoph M, Im Ellie, Cheng Shinta, Smith L, Hareth Nahi, Ferron-Brady Geraldine, Brouch Maria, Montes de Oca Rocio, Paul Sofia, Holkova Beata, Gupta Ira, Kremer Brandon E, Richardson Paul
Аннотация
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).
Предметные рубрики MeSH
AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB-Cell Maturation AntigenClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedMulticenter Studies as TopicMultiple MyelomaNeoplasm Recurrence, LocalRandomized Controlled Trials as TopicReceptors, OX40Research DesignTetrahydronaphthalenesValineYoung Adult